Why the study?
Does OPC-18790 improve diastolic chamber stiffness compared to dobutamine in patients with idiopathic dilated cardiomyopathy?
Population
17 patients with idiopathic dilated cardiomyopathy (DCM)
Comparison
OPC-18790 intravenous infusion vs Dobutamine intravenous infusion
Design
RCT, randomly assigned
Follow-up
acute (during drug administration)
Authors
Loading...
OPC-18790 may be favored over dobutamine for acute diastolic effects in idiopathic dilated cardiomyopathy; extends PDE inhibitor comparisons in heart failure.
Does OPC-18790 improve diastolic chamber stiffness compared to dobutamine in patients with idiopathic dilated cardiomyopathy?
OPC-18790, a novel phosphodiesterase inhibitor, has a more favorable acute effect on passive diastolic chamber stiffness than dobutamine in patients with idiopathic dilated cardiomyopathy.
Machii et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: